-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 13, Fosun Pharma announced that its controlling subsidiary, Fuhong Hanxuan, had received approval from NMPA to approve its recombinant anti-CD38 all-human monoclonal antibody injection for clinical trials for the treatment of multiple myeloma.
and Hanyu Pharmaceuticals intend to conduct Phase I clinical trials of the new drug in China (excluding Hong Kong, Macao and Taiwan) after the near-term conditions are met.
the new drug is the Group (i.e., the Company and its controlling subsidiaries/units, the same between 2) independently developed Daretoyu monoclonal antibody biosynthesis drug, intended for the treatment of multiple myeloma.
the date of this announcement , the D'Arreto U.S. single resistance in China was a mega-® for Janssen-Cilag International NV , which was approved for listing in July 2019 .
Based on IQVIA CHPA data (provided by IQVIA, IQVIA is the world's leading provider of professional information and strategic consulting services for the pharmaceutical and health industry;
as of December 2020, the Group's cumulative research and development investment in the new drug at this stage is approximately RMB16.24 million (unaudited).